Japan Lifeline Co., Ltd. Announces Management Changes, Effective April 1, 2021
March 26, 2021 at 02:10 am EDT
Share
Japan Lifeline Co., Ltd. announced that at the board of directors meeting held on March 26, it has decided to make the following changes to its personnel. In addition, Japan Lifeline has made a change to the current operating officer system so that term of office is one year from April 1 to March 31 of the following year. As a result, the current six operating officers, whose term of office is June 30, 2021, will be dismissed on March 31 and reappointed on April 1 of the same year. changes in personnel (effective on April 1, 2021) Kunio Kuwahara from old position and title -Operating Officer, General Manager of Ichihara R&D and Manufacturing Department of R&D and Manufacturing Headquarters to new position and title of Operating Officer, General Manager of Ichihara R&D and Manufacturing Department of R&D and Manufacturing Headquarters; Tsutomu Hoshino from old position and title -Operating Officer, Associate Senior General Manager of Arrhythmia Business Unit, General Manager of Arrhythmia Sales Department to new position and title of Operating Officer, Associate Senior General Manager of Arrhythmia Business Unit, General Manager of Arrhythmia Sales Department; Takahiko Suzuki from old position and title -Operating Officer, Senior Manager of West Japan Sales Division of Arrhythmia Sales Department of Arrhythmia Business Unit, Senior Branch Manager of Chugoku Branch to new position and title of Operating Officer, Senior Manager of EP Sales Promotion Division of Arrhythmia Business Unit, Senior Manager of West Japan Sales Division; Naohiro Nakada - from old position and title- Operating Officer, Senior Manager of EP Department of Arrhythmia Business Unit - to new position and title of Operating Officer Operating Officer, Senior Manager of EP Department of Arrhythmia Business Unit, General Manager of EP Marketing Division; Takashi Ito -from old position and title-Operating Officer, General Manager of CRM Department of Arrhythmia Business Unit to new position and title of Operating Officer, General Manager of CRM Department of Arrhythmia Business Unit; and Tatsuya Murase from old position and title -Operating Officer, General Manager of CVE Department of CV Business Unit, General Manager of CVE Marketing Division to new position and title of Operating Officer, General Manager of CVE Department of CVG Business Unit, General Manager of CVE Marketing Division. New Appointment: Kenji Mori from Old position and title of General Manager of Research & Development Department of R&D and Manufacturing Headquarters, General Manager of R&D Division II to New position and title of Operating Officer, General Manager of Research & Development Department of R&D and Manufacturing Headquarters, General Manager of R&D Division II; and Toshihiro Miyake from Old position and title of General Manager of Regulatory Affairs Division of Regulatory Affairs Headquarters to New position and title of Operating Officer, General Manager of Regulatory Affairs Division of Regulatory Affairs Headquarters.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.